The global Active Pharmaceutical Ingredient market is projected to reach USD 248.3 billion by 2025 from USD 187.3 billion in 2020, at a CAGR of 5.8% during the forecast period, according to a new report by MarketsandMarkets™. The rising drug RD, the increasing incidence of chronic diseases, the growing importance of generics, and the increasing uptake of biopharmaceuticals. On the other hand, unfavorable drug price control policies across various countries and high manufacturing costs are expected to restrain the growth of this market are the major factors driving the growth of this market.

Browse in-depth TOC on "Active Pharmaceutical Ingredient Market”
412 – Tables
39 – Figures
337 – Pages

In 2019, the innovative APIs segment accounted for the largest share of the Active Pharmaceutical Ingredient market

Based on type, the Active Pharmaceutical Ingredient market is segmented into innovative and generic APIs. The innovative APIs segment accounted for the largest share of the global Active Pharmaceutical Ingredient market in 2019. Increased FDA approvals for new molecular entities, high price of innovative APIs as compared to the generic drugs, increased focus on RD by the innovator API companies are the factors contributing towards the growth of the innovative APIs segment.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=263

The oncology segment is expected to grow at the highest CAGR during the forecast period

Based on application, the Active Pharmaceutical Ingredient market is segmented into communicable diseases, oncology, cardiovascular diseases, diabetes, pain management, chronic respiratory diseases, and other therapeutic application. neurology, immunology, hematology, critical care, pulmonology, hemato-oncology, rheumatology, and other applications. In 2019, the oncology segment is expected to register the highest CAGR during the forecast period. Growth in this market segment is driven by the increasing demand for highly potent APIs (HPAPIs) for the treatment of cancer.

North America was the largest regional market for Active Pharmaceutical Ingredient market in 2019

The global Active Pharmaceutical Ingredient market is segmented into North America, Europe, Asia, Latin America, and Rest of the World. In 2019, North America accounted for the largest share of the Active Pharmaceutical Ingredient market, followed by Europe and the Asia. The large share of North America in the global market is attributed to the growing incidence of preventable chronic diseases, increasing government focus on generic drugs, rising demand for biologics and specialty drugs, and technological advancements in the manufacturing processes of APIs. However, the market in the Asia is expected to grow at the highest CAGR during the forecast period. This can be attributed to the low manufacturing costs, growth in the increase in disposable income, the high prevalence of lifestyle- and age-related diseases, and government efforts to reform healthcare industry.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=263

The global Active Pharmaceutical Ingredient market is highly consolidated. Prominent players in the Active Pharmaceutical Ingredient market include Pfizer Inc. (US), Novartis International AG (Switzerland), Merck Co. (US), Teva Pharmaceutical Industries Ltd. (Israel), Mylan N.V. (US), Boehringer Ingelheim (Germany), F. Hoffmann-La Roche AG (Switzerland), Sanofi (France), AbbVie (US), Eli Lilly and Company (US), AstraZeneca (UK), Bristol-Myers Squibb (US), and GlaxoSmithKline plc (UK).

Browse Adjacent Market: Pharmaceuticals Market Research Reports Consulting

Related Reports:

Pharmaceutical Excipients Market by Product (Organic Chemicals (Carbohydrates), Inorganic Chemicals (Calcium Phosphate)), Functionality (Fillers, Binders, Lubricants, Preservatives), Formulation (Tablets, Capsules, Parenteral) - Global Forecast to 2027
https://www.marketsandmarkets.com/Market-Reports/pharma-excipients-market-956.html